Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae. It is also used to protect adults and the elderly against invasive disease and pneumonia caused by S.

PCV20 (Prevnar20®) is a sterile suspension of saccharides from 20 serotypes of S. pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) individually linked to a nontoxic variant of diphtheria toxin known as CRM197.

Prevnar 13 was approved for use in the European Union in December 2009. In February 2010, Prevnar 13 was approved in the United States to replace Prevnar (PCV7), the pneumococcal 7-valent conjugate vaccine (PCV7).

About Prevnar 13 Prevnar 13 was first introduced for use in infants and young children in December 2009 in Europe and in February 2010 in the U.S., and it is now approved for such use in nearly 120 countries worldwide.

Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12-15 months of age. a Dose 1 may be given as early as 6 weeks of age. b The recommended dosing interval is 4 to 8 weeks. c The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.

Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12–15 months of age. Dose 1 may be given as early as 6 weeks of age. The recommended dosing interval is 4 to 8 weeks. The fourth dose should be administered at approximately 12–15 months of age, and at least 2 months after the third dose.

PREVNAR® 13 (pneumococcal 13-valent conjugate vaccine - diphtheria CRM197 protein) | Pfizer Medical Information - US.

Pfizer Canada PREVNAR 13 (pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) | Pfizer Canada.

PREVNAR® 13 (pneumococcal 13-valent conjugate vaccine - diphtheria CRM197 protein) | Pfizer Medical Information - US.

PCV vaccines are recommended to be given first because this sequence provides the best immune response to both PCV and PPSV23 vaccines.

Active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children 6 years through 17 years of age (prior to the 18th birthday). Active immunization for the prevention of pneumonia and invasive disease caused by S.